End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
15,220 KRW | -0.59% | +1.67% | +4.39% |
Business Summary
Sales per Business
KRW in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Pharmaceutical
100.0
%
| 9,320 | 100.0 % | 17,064 | 100.0 % | +83.09% |
Sales per region
KRW in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
South Korea
100.0
%
| 9,320 | 100.0 % | 17,064 | 100.0 % | +83.09% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Dong-Gi Lee
FOU | Founder | 52 | 10-01-31 |
Jun-Hyun Park
CTO | Chief Tech/Sci/R&D Officer | 39 | - |
Young-Hye Baek
BRD | Director/Board Member | 49 | - |
Chung-Gil Kang
BRD | Director/Board Member | 53 | - |
Sin-Young Park
BRD | Director/Board Member | 59 | - |
Sung-Hwa Hong
AUD | Comptroller/Controller/Auditor | 67 | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Yang-Gyoon Kim
BRD | Director/Board Member | 57 | - |
Chang-Soo Yoon
BRD | Director/Board Member | 51 | - |
Dong-Gi Lee
FOU | Founder | 52 | 10-01-31 |
Sin-Young Park
BRD | Director/Board Member | 59 | - |
Chung-Gil Kang
BRD | Director/Board Member | 53 | - |
Young-Hye Baek
BRD | Director/Board Member | 49 | - |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 442,128 | 0 | 0 | 73.23 % |
Stock B | 1 | 16,526,595 | 12,102,177 ( 73.23 %) | 0 | |
Stock C | 0 | 431,583 | 0 | 0 |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
PCL, INC. 7.65% | 4,132,665 | 7.65% | 4,475,718 $ |
Company contact information
OliX Pharmaceuticals, Inc.
#1014 Ace Gwangkyo Tower1 17 Daehak 4-ro
16226, Suwon-si
+
http://www.olixpharma.comSector
1st Jan change | Capi. | |
---|---|---|
+4.39% | 183M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+0.79% | 22.15B | |
-17.37% | 21.02B | |
-7.98% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- A226950 Stock
- Company OliX Pharmaceuticals, Inc